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Abstract
Breast cancer treatment has improved rapidly through the years, starting from surgery, 
to hormonal therapy, to targeted therapy. Despite this, tumor metastasis remains the 
highest cause of breast cancer–related death. The current regime to deter metastasis is 
through adjuvant therapy, but such therapy frequently yields undesirable side effects. 
As such, prognostic markers for metastasis are important to stratify patients for adju-
vant therapy so as to ameliorate the standard of living of patients with low metastatic 
potential. So far, only a few well-characterized prognostic biomarkers for metastasis are 
used in clinics. This chapter will cover both established and novel prognostic biomark-
ers for breast cancer metastasis and metastatic breast cancer prognosis. The potential of 
using these biomarkers as predictive biomarkers or new targeted therapy will also be 
discussed.
Keywords: metastasis, prognostic biomarker, metastatic breast cancer, relapse, 
recurrence, distant-free metastasis survival, overall survival
1. Introduction
Breast cancer remains the most frequently diagnosed cancer in women worldwide. In the 
United States (US), the American Cancer Society estimates that in 2018, the highest frequency 
of cancer diagnosed and the second highest cancer-related death in women will be breast 
cancer, at 30 and 14%, respectively [1]. Breast cancer survival statistics have improved tre-
mendously over the years with a decrease of 39% mortality from 1989 to 2015 [1, 2]. This is 
mainly due to mammogram screening resulting in early detection and intervention [3, 4]. 
When diagnosed at a localized stage, the 5-year survival rate is 99% [5]. However, metas-
tasis remains the major cause of mortality in breast cancer patients. Five-year survival rate 
decreases dramatically according to spread of cancer, with regional and distant metastasis 
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spreads at 85 and 27%, respectively [1]. Ten-year survival rate for stage IV metastatic breast 
cancer female patients is only approximately 13% [6]. These statistics indicate that metastasis 
is the major barrier against breast cancer eradication.
Breast cancer can be categorized largely into two types, in situ and invasive breast cancer [2]. 
In situ represents the subset in which the cancer is still confined within the transformed origin. 
Ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS) are the two main types 
of frequently diagnosed in situ breast cancer at 83 and 13%, respectively [2]. DCIS, as its name 
suggests, refers to cancer originating from the epithelial cells of the breast ducts, whereas 
LCIS arises from the lobules of the breast. On the other hand, majority (80%) of breast cancer 
will become invasive, i.e., that they will outgrow into surrounding breast tissue [2].
The primary treatment for in situ breast cancer is surgery. This includes lumpectomy where 
only the tumor and surrounding tissues are removed or mastectomy in which the entire 
breast is removed [2]. Very often, radiation and adjuvant therapy are recommended after sur-
gery to prevent recurrence and to eliminate breast tumor cells which might have spread [2]. 
Examples of adjuvant therapy are cytotoxic chemotherapy, hormone therapy, and targeted 
therapy [2, 3]. These will be discussed in more detail in the later sections.
Although adjuvant therapy has been shown to be beneficial in preventing metastatic recur-
rence, the patient’s quality of life is severely affected in many cases. Side effects include 
fatigue, osteoporosis, increased thromboembolic events, premature menopause, weight gain, 
and mild memory loss [7, 8]. Although as many as 80% of patients receive adjuvant treat-
ment, only 40% of them relapse and die from metastatic breast cancer indicating that majority 
of patients are over-treated and suffer unnecessary side effects [3]. In addition, only 15% of 
patients treated with tamoxifen after surgery will have distant recurrence, indicating that 85% 
of patients will be overtreated if chemotherapy is mandatory [9].
One solution to overcome unnecessary treatment is through identifying patients with high 
and low risk of metastasis using prognostic biomarkers. Current established metastasis bio-
markers are available but have poor predictive power [10]. With new concepts such as gene 
expression profiling and circulating tumor cells, new prognostic markers with greater accu-
racy could be identified. The following sections will describe established markers as well as 
new upcoming markers for the prediction of survival, metastasis risk, and recurrence risk for 
metastatic breast cancer. Current and potential use of these markers in the clinic as predictive 
biomarkers for treatment and as potential targets is also discussed.
2. Established biomarkers
2.1. Tumor size and lymph node status
The tumor-node-metastasis (TNM) staging system is commonly used to stage breast cancer 
progression during initial diagnosis [11]. It constitutes a manner to measure the aggressive-
ness of the cancer. The abbreviations represent different characteristics of the cancer. “T” rep-
resents tumor size, “N” indicates the number of lymph nodes that the cancer has spread to, 
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and “M” conveys the presence of distant metastasis [11]. In the absence of distant metastasis 
(“M”), tumor size and lymph node status are established prognostic markers for likelihood of 
metastasis. Specifically, primary tumors that are less than 2 cm have low prognosis for devel-
oping into metastatic breast cancer. Tumor sizes of 2–5 cm and more than 5 cm have a high 
and very high likelihood of progressing into metastatic cancer respectively [12–15]. Likewise, 
breast cancer patients with no detectable lymph node metastases are at low risk of distant 
metastasis. Patients with presence of lymph node metastasis have high risk of metastasis, and 
more than four lymph node metastases represent a high probability progressing to distant 
metastasis [12–15].
2.2. Histological grade
Histological grade is the determination of how differentiated a tumor is. As the histologi-
cal grade increases, the tumor appears more poorly differentiated [16]. The determination of 
histological grade is performed by a trained pathologist using certain characteristics of the 
cancer tissue section such as mitotic count, extent of tubule or gland formation, and nuclear 
pleomorphism [16]. Histological grade 1 tumors have low risk of metastasis, while grade 2 
and 3 tumors have intermediate- and high-risk tumors [12, 14, 17]. Integrating histological 
grade with the aforementioned tumor size and lymph node status, several prognostic indices 
such as the Nottingham Prognostic Index, the Kalmar Prognostic Index, and the St. Gallen 
guidelines have been established and used in clinics to aid in adjuvant treatment decision [16].
2.3. Angioinvasion
Angioinvasion is the presence of blood vessel invasion by cancer cells. In lymph node nega-
tive patients, angioinvasion has some prognostic value in predicting metastasis [18, 19]. In 
particular, tumor emboli in more than three blood vessels suggest a high risk of metastasis 
[18, 19]. Although these tumor characteristics (tumor size, lymph node status, histological 
grade, and angioinvasion) represent a simple and cheap method to predict metastasis, statis-
tics show that these prognostic factors only accurately predict metastatic outcome in 30% of 
patients [3, 16]. As such, better prognostic markers are required for the remaining 70%.
2.4. Molecular subtype
Invasive breast cancer can be divided into four main molecular subtypes based on the pres-
ence of hormone receptors (estrogen or progesterone) (HR) and human epidermal growth 
factor receptor 2 (HER2) [2]. The four subtypes are luminal A (HR+/HER2−), luminal B (HR+/
HER2+), HER2 enriched (HR−/HER2+), and triple negative (HR−/HER2−) at frequencies of 
71, 12, 5, and 12% of all invasive breast cancer, respectively [2].
In general, luminal A and B subtypes are associated with the most favorable prognosis and 
least aggressive, followed by HER2 enriched and triple negative sequentially [2, 20–23]. In a 
6.9-year follow-up study on patients who were initially diagnosed with localized breast can-
cer, the frequency of distant metastasis increases progressively in the following order, luminal 
A (6.4%), luminal B (12.1%), HER2-enriched (19.2%), and triple negative (27.4%) [24]. Another 
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study involving metastatic breast cancer found that luminal A exhibited the longest survival 
rate (34.4 months), followed by luminal B (24.8 months), HER2 enriched (19.8 months), and 
triple negative (8.8 months) [25]. Similarly, follow-up on patients with early stage breast 
cancer found that survival with distant metastasis showed similar patterns [26]. Luminal A 
survived the longest duration (2.2 years), followed by luminal B (1.6 years), HER2 enriched 
(0.7 years), and triple negative (0.5 years) [26]. These findings strongly suggest that molecular 
subtype correlates with metastasis rate and survival and can be used as a prognostic marker 
for metastasis.
In fact, molecular subtypes are already routinely used in clinics as prognostic and predic-
tive biomarkers for overall survival and stratification of patients to targeted therapy [2]. As a 
predictive biomarker, patients who are either HR+ or HER2+ benefit majorly due to targeted 
therapy options. The estrogen receptor (ER) in breast cancer plays an important tumor pro-
moting role by activating downstream intracellular signals for proliferation and survival [27]. 
As such, patients with ER+ breast cancer are routinely treated with selective estrogen receptor 
modulators (SERMs) [8]. Tamoxifen is the first approved SERM to be used for the treatment 
of ER+ metastatic breast cancer [8]. Five-year use of tamoxifen as an adjuvant significantly 
reduced local and distant recurrences by 40–50% making ER status both a prognostic and 
predictive biomarker [28].
Apart from using SERMs, aromatase inhibitors (AIs) are an alternative targeted treatment 
for ER+ breast cancer patients. These inhibitors function to block estrogen production by 
inhibiting the aromatase enzyme [8]. Studies have found that there is no difference in effi-
cacy and time to distant recurrence when compared to tamoxifen treatment [29]. In addition, 
both tamoxifen and AI treatment are associated with increased overall survival and distant 
metastasis-free survival [30]. Since ovaries are the main source of estrogen, ovarian surgery, 
ovarian irradiation, or ovarian suppression by drugs have been shown to improve therapeutic 
outcomes [2, 31]. Particularly, in a clinical study, 5-year disease free survival was as high as 
91.1%, when ER+ premenopausal women were treated with adjuvant ovarian suppression 
combined with AI treatment [31]. Additionally, use of AI with ovarian suppression signifi-
cantly decreased recurrence as compared to tamoxifen with ovarian suppression [31]. These 
evidences strongly illustrate the use of ER status for metastatic survival prognosis and for 
tamoxifen or AI adjuvant therapy decision.
Historically, HER2-enriched metastatic breast cancer is associated with high aggressive-
ness and has a poor prognosis [2, 32–34]. That is until the first anti-HER2 targeted therapy 
Trastuzumab clinical trial emerged, which showed improved clinical outcomes by includ-
ing Trastuzumab into adjuvant treatment with chemotherapy for HER2-enriched metastatic 
breast cancer [35]. Trastuzumab is a monoclonal antibody which binds and targets the extra-
cellular portion of the HER2 receptor protein [8]. Specifically, combining Trastuzumab with 
standard chemotherapy for HER2-enriched metastatic breast cancer resulted in increased 
time to progression, overall survival, and duration of response [35, 36].
In recent years, many new biologics targeting HER2 have been approved for advanced 
metastatic HER2-enriched breast cancer [37]. Pertuzumab, another monoclonal antibody 
which inhibits HER2 dimerization, is approved for use in combination with trastuzumab 
Cancer Metastasis98
in metastatic HER2+ breast cancer [38]. Treatment of HER2-enriched metastatic breast can-
cer patients using a combination of Pertuzumab, Trastuzumab, and Docetaxel resulted in a 
significant increase in median overall survival of 15.7 months as compared to just treating 
with Trastuzumab and Docetaxel [38]. Increase in progression free survival and duration of 
response by 6.3 months and 7.7 months, respectively, were also noted when Pertuzumab was 
used in combination [38].
Another recently approved biologic for HER2+ advanced breast cancer is the antibody-drug 
conjugate T-DM1 [39, 40]. It involves the ingenious exploitation of Trastuzumab’s specific-
ity to HER2+ breast cancer cells to deliver the linked cytotoxic microtubule-inhibitory drug 
DM1 directly to HER2+ cancer cells [39, 40]. It is particularly effective in slowing disease 
progression for HER2+ advanced breast cancer patients who were initially treated with first 
line Trastuzumab/Taxane combination [39]. Progression free survival when treated with 
T-DM1 was significantly longer (9.6 months) as compared to the standard second line treat-
ment (6.4 months) [39]. Overall survival improved significantly from 25.1 to 30.9 months 
[39]. Additionally, patients treated with T-DM1 experienced less toxicity as compared to the 
standard second line treatment [39]. Taken together, it is recommended that the Docetaxel/
Trastuzumab/Pertuzumab combination be used as a first line choice and T-DM1 as a second 
line therapy [37].
The importance of HER2-targeted therapy for metastatic breast cancer is further empha-
sized by the finding that as many as 16% of initially HER2 negative breast cancer exhibits 
HER2 expression upon metastasis [37]. This indicates that HER2-targeted therapies could 
be extended to treat metastasis in this select group of patients, and it is recommended in 
clinics that HER2 status in metastatic cells be tested by fluorescence in situ hybridization or 
immunohistochemistry staining to evaluate eligibility for HER2-targeted therapy regardless 
of initial subtype of the primary tumor [37]. Overall, these findings highlight the importance 
of using HER2 status as both a prognostic and predictive biomarker in clinics for metastatic 
breast cancer.
As for triple negative cancers which do not currently have their own targeted therapy, neoad-
juvant anthracycline-based chemotherapy has been found to benefit this group [41]. Clinical 
response in triple negative was 85% as compared to luminal (47%) or HER2 positive (70%), 
and all subtypes had equally good prognosis after treatment [41]. However, this only applies 
to triple negative patients who exhibited pathologic complete response from treatment, which 
constitutes only 27% [41]. As such, for majority of triple negative patients who do not display 
complete pathologic response after chemotherapy, more studies need to be done to discover 
targets specific against triple negative breast cancer.
In addition to metastasis frequency and survival, molecular subtypes could potentially pre-
dict distant metastasis tumor sites and distant relapse sites. With the exception of triple nega-
tive basal subtype, bone metastasis is the most common metastasized site among all subtypes, 
with the luminal subtypes displaying the highest frequency [26, 42]. Correspondingly, bone 
is the most frequent metastatic relapse site, with luminal subtypes exhibiting the highest 
frequency [43, 44]. The subtypes with the highest brain and lung metastasis rates are HER2 
enriched and triple negative [26]. Among all subtypes, metastatic lung and brain relapse are 
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highest for triple negative [43, 44]. HER2-enriched subtype has the highest liver metastasis 
rate, whereas triple negative has more distant lymph node metastasis as compared to other 
subtypes [26, 42]. The importance of determining site of metastasis is covered in the next 
section.
2.5. Site of distant metastasis
The significance of predicting site of metastasis for metastatic breast cancer patients is high-
lighted by the intrinsic correlation with overall survival and survival after distant recur-
rence. In the following order, breast cancer patients with single site brain, lung or liver, and 
bone metastasis have the worst to best prognosis [42, 45]. Median overall survival rates for 
patients with brain, lung, liver, and bone metastasis are 11 months, 30 months, 31 months, 
and 41 months, respectively [42]. In addition, the survival trend holds true when patients are 
stratified based on HR indicating that it is independent of HR status [45].
Postmetastasis distant recurrence is also associated with the site of recurrence. In particular, 
first visceral (including brain) site recurrence is associated with a poorer prognosis as com-
pared to first bone recurrence with 3-year breast cancer specific survival (BCSS) rate at 13 (vis-
ceral) and 23% (bone), respectively [46]. When compared to recurrences closer to the primary 
tumor, first local and first lymph node recurrences 3-year BCSS are significantly higher at 83 
and 33%, respectively, indicating that metastatic site proximity to primary tumor origin site is 
also strongly linked to prognosis [46].
Apart from the site of distant metastasis, the number of initial metastatic sites is also prog-
nostic of survival. Patients with multiple metastatic sites have significantly poorer overall 
survival than patients with single metastatic site in both HR+ (9 months) and HR− (5 months) 
patients [45]. Multiple metastatic sites are also more prone to occur in HR− patients, which 
are in line with the poorer prognosis of HR− patients [45].
2.6. Age of diagnosis
Indubitably, as with many diseases, age is a major determinant of prognosis in metastatic 
breast cancer. Survival rate in stage IV invasive breast cancer patients significantly decreases 
with age [6]. Ten-year breast cancer specific survival rates for three groups of stage IV patients 
namely, below the age of 40 years, between 41 and 50 years, and between 51 and 70 years, 
drops from 15.7 to 14.9% to 11.7%, respectively [6]. Likewise, another study found similar 
trends in metastatic breast cancer patients, where overall survival decreases significantly with 
age, from 32 months (age < 50 years) to 25 months (50–69 years) to 16 months (>69 years) [47]. 
One plausible explanation is that younger patients are more physically fit to endure treatment 
than elder patients, and this is supported by a significantly higher rate of surgery and radia-
tion therapy underwent by patients below 69 years [47].
Age is also a determinant in the prediction of distant metastasis site. In accordance with the 
age-related survival trend, frequency of the deadlier lung metastasis increases significantly 
with age from 5.9% (age < 50 years) to 7.6% (50–69 years) to 14.2% (> 69 years), respectively 
[47]. Correspondingly, a significantly lower rate of the less lethal distant lymphatic metastasis 
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is observed as age increases with rates at 7.3, 5.4, and 4.0% for patient age of less than 50 years, 
50–69 years, and more than 69 years, respectively [47]. Metastasis to the brain, liver or bone is 
not dependent on age [47]. Interestingly, multiple metastatic sites, which are associated with 
poorer prognoses, occurred more frequently in younger patients (<69 years) than in older 
patients (>69 years) at approximately 34.9 (age < 50 years) and 36.2% (50–69 years), and 28.3% 
(>69 years), respectively [47]. This discrepancy could be explained by the higher rate of treat-
ment in younger patients, suggesting that patients with multiple metastatic sites could benefit 
from surgery and radiation therapy [47]. Overall, age at diagnosis is a strong independent 
prognostic factor for metastatic breast cancer patient survival and for predicting the site of 
metastasis [47].
2.7. Urokinase-type plasminogen activator (uPA) and plasminogen activator type 1 
inhibitor (PAI-1)
The urokinase-type plasminogen activator (uPA), which is a serine protease, and its inhibitor 
plasminogen activator type 1 inhibitor (PAI-1) are involved in the degradation of extracellular 
matrix, which is a crucial process in the initial stages of metastasis [48]. Although PAI-1 inhib-
its uPA activity, it has been found to promote tumor invasion and angiogenesis through other 
means [49]. As such, both uPA and PAI-1 could potentially be used as metastasis prognostic 
markers. Supporting this, high uPA and PAI-1 levels are correlated with lower metastasis-free 
survival and overall survival in breast cancer patients [50–54]. In addition to being a prognos-
tic marker, both uPA and PAI-1 could be used as predictive biomarkers for adjuvant therapy. 
In a study, patients with high uPA and PAI-1 levels benefited significantly from adjuvant 
chemotherapy compared to patients with low uPA and PAI-1 levels [55]. This indicates that 
patients with high uPA and PAI-1 levels could be treated with chemotherapy after surgery.
Furthermore, since uPA functions by binding to its receptor, urokinase plasminogen acti-
vator receptor (uPAR), the interaction could be exploited for metastasis targeted therapy. 
Indeed, one of the developments in this area is the use of an antibody to target uPAR [56, 57]. 
Remarkably, the antibody is shown to inhibit invasion of cancer cells and induce apoptosis, 
indicating its potential use for metastatic breast cancer [57].
2.8. Gene expression profiling
With the advent of gene expression profiling, treatment options are expected to shift toward 
a more personalized approach [58]. Although the idea of sequencing every cancer patient 
for individualized prognosis and treatment remains elusive, using multigene signatures to 
stratify patients into groups with different prognosis and therapeutic options has been very 
well established and routinely used in clinics. The first report of using high throughput meth-
ods for stratification of patients started in diffuse large B-cell lymphoma (DLBCL) patients 
[59, 60]. Based on their gene signatures from microarray, two subtypes of DLBCL, namely 
germinal center B-like DLBCL and activated B-like DLBCL, were characterized and were 
prognostic of overall survival [59]. In fact, molecular subtypes of breast cancer (mentioned in 
previous sections) were also identified using microarray-based gene expression profiling and 
are routinely used in clinical settings for prognosis [20–23].
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Following the clinical success of using multigene signatures to identify and stratify patients 
with different clinical outcomes, two different gene expression profiling panels have emerged 
and are currently used in clinical settings. Each platform relies on different gene panel and is 
routinely used for predicting metastasis risk, local and distant metastasis recurrence, and for 
treatment decisions [61]. These are Oncotype DX and MammaPrint. Other gene expression 
profiling panels such as the PAM50 [62], two-gene expression ratio [63], and MapQuant DX 
[64] are not covered here [65].
Oncotype DX is the most widely used multigene panel tool for the prediction of distant recur-
rence risk in the United States [2]. It is a reverse-transcription-polymerase-chain-reaction 
(RT-PCR) based assay which measures the expression of 16 cancer-related genes and 5 refer-
ence genes in tumor tissue [9]. Based on the expression level of the 21 genes, an algorithm 
computes a recurrence score which quantifies the probability of distant recurrence [9]. Using 
the recurrence score, a patient with higher score is considered high risk and would likely 
benefit from chemotherapy as compared to a patient with lower score who could avoid che-
motherapy altogether [2, 9].
Oncotype DX is currently utilized in clinics to predict distant recurrence for ER+, lymph node 
negative breast cancer patients who had prior tamoxifen treatment [9]. In the original paper, 
51% of ER+, lymph node negative, tamoxifen-treated patients were classified under low-risk, 
and indeed, only 6.8% of this group had distant recurrence within 10 years [9]. This is in com-
parison with the high-risk group consisting of 27% of patients who had a 30.5% distant recur-
rence rate within 10 years [9]. In addition, recurrence score could also predict overall survival 
and relapse-free survival [9]. In support, a recent prospective validation study showed that 
Oncotype DX could potentially select low recurrence patients with high probability to forgo 
chemotherapy [66]. Five-year recurrence free rate from all sites and distant site, for patients 
with low recurrence score and only underwent tamoxifen treatment, were a high 98.7 and 
99.3%, respectively [66]. Overall survival and invasive disease-free rates were up to 98 and 
93.8%, respectively [66]. These findings show the clinical applicability of Oncotype DX to 
select for patients who could forgo chemotherapy and its unnecessary side effects.
The second most commonly used multigene panel for prognosis and treatment decision is 
MammaPrint [65, 67]. It utilizes an oligonucleotide microarray to measure the expression of 
70 genes to identify gene signatures that stratify patients into a “good” or “poor” progno-
sis that predicts metastasis risk in lymph node negative early breast cancer patients [68–72]. 
Sensitivity and specificity of MammaPrint are 91 and 73%, respectively [3]. Genes involved 
in “poor” prognosis signature include angiogenesis, cell cycle, invasion, and metastasis [69].
In one of the earlier studies depicting the prognostic value of MammaPrint patient stratifica-
tion, 10-year distant metastasis free probabilities were lower for “poor” prognosis group at 
50.0% than in “good” prognosis group at 85.2% [68]. Overall survival rates were also signifi-
cantly different between groups at 50.6 and 85.2% for “poor” and “good” prognosis groups 
correspondingly [68].
In a follow-up study with longer term survival statistics, 25-year distant metastasis free 
survival was significantly lower for “poor” prognosis group (41.6%) as compared to “good” 
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prognosis group (60.4%) [72]. Overall survival at 25 years also showed the same trend at 44.5 
and 57.3% for “poor” and “good” prognosis groups, respectively [72]. These statistics show 
the relevance of using MammaPrint in clinical settings as a prognostic biomarker for metas-
tasis risk and overall survival. It could also be applied as a predictive biomarker for selecting 
patients with “poor” prognosis for adjuvant treatment.
Overall, the importance of multigene expression profiling tools for prognosis and treatment 
decision in the clinic is apparent when compared to classical clinicopathological parameters 
which are determined by a trained pathologist. It is found that low agreement exists among 
pathologists in breast cancer grading as tumor grading includes a degree of subjectivity [9]. 
A study comparing the different gene expression profiling tools found that although dif-
ferent gene sets were used among different panels, 4 out of 5 (including Oncotype DX and 
MammaPrint) achieved high concordance in relation to predicting outcomes [73]. As such, 
tools like Oncotype DX and MammaPrint stand out in this aspect.
3. New biomarkers
3.1. Improved gene expression profiling
Although the first generation gene expression profiling tools, Oncotype DX, and MammaPrint 
have greatly advanced the prognosis of breast cancer patients for metastasis risk and distant 
recurrence, a major drawback is that they are unable to accurately predict late distant recur-
rence of more than 5 years [74]. Two newer gene expression profiling tools, EndoPredict and 
The Breast Cancer Index, have emerged successful in this aspect [74].
EndoPredict is a RT-PCR-based assay, which measures the expression of eight cancer genes 
and three housekeeping genes to stratify patients into high- and low-risk distant recurrence 
groups [75–77]. A newer version of it combines the 11 gene expression with tumor size and 
nodal status to calculate a risk score termed the EPclin [76]. Patients with an EPclin score of 
less than 3.3 are classified as low-distant recurrence risk, while more than or equals to 3.3 are 
classified as high-distant recurrence risk [76]. The EPclin score is the best predictor of late 
relapse (>5 years), when compared to the earlier version of EndoPredict or to nodal status 
and tumor size alone [76]. Metastasis free survival for short term (less than 5) and long term 
(5–12 years) are also significantly different between the EPclin-stratified high- and low-risk 
groups, validating its applicability to predict metastasis [76]. In addition, distant recurrence 
free rates at 10 years in EPclin low-risk group is higher than in EPclin high-risk group, at 
98.20 and 87.69%, respectively, depicting its ability to predict distant recurrence for longer 
time frames [76].
The breast cancer index (BCI) is another RT-PCR-based assay, which combines two inde-
pendent biomarkers namely a set of five cell cycle genes and the HOXB13 and IL17BR gene 
ratio to determine the recurrence probability of early stage ER+, lymph node negative breast 
cancer patients [63, 78, 79]. Independently, both the five gene panel and the two gene ratio are 
associated with distant metastasis free survival rates [78]. However, when combined, three 
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groups could be formed, low-, intermediate-, and high-risk groups, which are significantly 
predictive of metastasis occurrence [78]. Ten-year distant metastasis free survival for low-, 
intermediate-, and high-risk groups are 98, 87, and 60%, respectively [78]. Additionally, in 
a study comparing the prognostic ability of BCI with Oncotype DX and another gene panel, 
BCI emerged as the only test capable of significantly predicting both early and late distant 
metastasis recurrence, whereas the other two were only able to predict early recurrence [80].
In general, both EndoPredict and BCI seem to be superior as compared to the first-generation 
counterparts. This is particularly in terms of predicting longer term distant recurrence while 
also predictive of early recurrence [74].
3.2. Circulating tumor cells
An essential part of distant metastasis requires cells from the primary tumor to migrate into 
the bloodstream to spread throughout the body till it finds a secondary site to establish a sec-
ondary tumor [3]. As such, it is not surprising that circulating tumor cells (CTCs) in peripheral 
blood could be utilized as a prognostic indicator. The peripheral blood also represents an 
easily accessible region, which is an added advantage of using CTCs for prognosis [81].
The history of CTCs dates back as far as the nineteenth century when researchers have just 
begun to study the concept of tumor cells shedding from primary tumor [82, 83]. Today, there 
are multiple platforms for the isolation and detection of CTCs in the peripheral blood in clini-
cal use [84]. Termed the ”golden standard”, the CellSearch system is the only FDA-approved 
platform for such purpose in breast, prostate, and colorectal cancer [84]. The problems associ-
ated with detection of CTCs are its rare amount in the peripheral blood and the absence of a 
universal surface marker for different cancer cell types [84]. The CellSearch system overcomes 
these sensitivity and specificity issues through the use of an antibody to capture CTCs and 
poststaining the captured CTCs for identification [84]. Specifically, an avidin-biotin anti-
EpCAM antibody complex is used to bind CTCs followed by a magnetic capture to isolate 
CTCs [84–86]. Following which, the captured pool of cells is stained with DAPI and cytokera-
tins CK8, CK18, and CK19 to select for nucleated and epithelial cells, respectively [84–86]. 
Additionally, to differentiate from circulating white blood cells, anti-CD45 is used to further 
isolate CTCs [84–86]. Other systems using size [87–89], density [90], and microfluidic [91] 
characteristics of CTCs for isolation exist but are not covered in this chapter [81].
Enumerating CTCs in peripheral blood holds immense potential in clinics. The early paper 
using the CellSearch system to study progression of metastatic breast cancer provided many 
useful information [86]. The first thing noted was that CTCs were only present in metastatic 
breast cancer patients. Two or more CTCs per 7.5 mL of blood were present in metastatic 
breast cancer patients, while CTCs were rare (less than or equal to 1) in both healthy and 
benign breast cancer women [86]. Next, CTCs were independent prognostic marker of over-
all survival and progression-free survival [86]. After new treatment, patients with high level 
of CTCs (CTCs ≥5) had a significantly lower median progression-free survival and overall 
survival than patients with low level of CTCs (CTCs <5), at 2.1 months versus 7.0 months for 
progression-free survival and 8.2 months versus >18 months for overall survival, respectively 
[86]. Additionally, the prognostic value of CTCs for overall survival and progression-free 
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survival is also validated in two other studies, wherein one of it is a prospective study with 
metastatic breast cancer patients who were not treated previously [92, 93].
In terms of treatment, median progression-free and overall survival differed significantly 
between patients with CTCs ≥5 before treatment and CTCs <5 after treatment (1st group) 
and patients with decrease in CTCs after treatment but still ≥5 after treatment (2nd group) 
[86]. Median overall survival and progression free survival for 1st group are 7.6 months 
and 14.6 months, and for the 2nd group, 2.1 months and 9.2 months, respectively [86]. This 
suggests that CTCs could potentially be used to measure treatment efficiency, although the 
authors cautioned against this interpretation [86]. Following this, two other studies have also 
observed CTCs as a predictor of therapy efficiency for metastatic breast cancer [94, 95].
3.3. TIP60
Tat-interactive protein 60 kDa (TIP60) is a haploinsufficient tumor suppressor involved in 
both early and late stage breast cancer [96–99]. In particular for late stage progression, TIP60 
is known to regulate epithelial to mesenchymal transition, an important pathway for cellular 
metastasis [96, 97]. Both in vitro and mouse models have shown that loss of TIP60 results in 
increased metastatic breast cancer cell migration and invasion, indicating that therapies to 
increase TIP60 in breast cancer could be a potential therapeutic approach for metastatic breast 
cancer [96, 97]. Additionally, the microRNA miR-22 inhibits the expression of TIP60, thereby 
making it a promoter of metastasis and a potential therapeutic target for metastatic breast 
cancer [97]. More importantly, both miR-22 and TIP60 are prognostic of overall survival and 
metastasis free survival [96, 97]. As such, both miR-22 and TIP60 expression levels would be 
invaluable tools in clinics to predict metastatic probability and prognosis of overall survival.
4. Future directions/conclusions
Using only clinicopathological characteristics for assessing metastasis risk, the St Gallen cri-
teria and National Institutes of Health criteria each classified a low 15 and 7% of lymph node 
negative breast cancer as low metastasis risk, respectively [3, 68]. However, after 10 years, up 
to 25% of the low-risk group developed distant recurrence [3, 68]. In addition, only slightly 
less than half (45%) of high-risk patients developed metastasis, indicating that the remaining 
55% of “high-risk” patients had adjuvant treatment and tolerated its unnecessary effects [3, 
68]. In contrast, using MammaPrint in the same cohort, a high 60% of total patients were 
categorized as low risk, out of which only 13% of these low-risk patients developed metastasis 
after 10 years, showing that as many as 52.2% of overall patients were safely spared from 
adjuvant therapy, as compared to 5.25 to 11.25% of overall patients stratified using clinico-
pathological characteristics [3, 68]. These findings clearly delineate the superiority of gene 
expression panels for prognosis as compared to just clinicopathological characteristics.
A more beneficial solution would be to combine both clinicopathological markers and multi-
gene expression profiling to have an additive or synergistic effect in prediction for the better-
ment of patient prognosis and prediction of treatment outcomes. An example is the multigene 
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expression EPclin risk score which combines its predecessor, the EndoPredict with tumor 
size, and nodal status to better predict distant metastatic recurrence as compared to if the 
markers were used individually [76].
However, a significant problem still exists in the field of prognosis for metastatic breast can-
cer. Many of the gene expression profiling tools, such as Oncotype DX and BCI, are suitable 
only for prediction of distant metastasis recurrence in ER+, lymph node negative metastatic 
breast cancers [74, 100]. As such, it represents a gap in the identification of prognostic mark-
ers for other subtypes. For this, newer markers like the detection of CTCs which does not 
discriminate between subtypes may be used. TIP60 which also does not discriminate between 
subtypes in risk-free survival rates [98] may be explored and could potential be used as a 
prognostic biomarker for breast cancer metastasis. Other upcoming biomarkers which are 
not discussed here such as blood-based biomarkers [101] and long noncoding RNA [102] also 
holds immense potential as prognostic markers in breast cancer metastasis.
Overall, the field of metastatic breast cancer prognosis has come a long way, beginning 
with clinicopathological markers to molecular subtypes to multigene expression profiling 
and eventually CTCs. Continuing on, it is likely that future direction for this field will 
entail combining existing biomarkers together or with newly identified biomarkers, lead-
ing to tremendous improvements in metastatic breast cancer prognosis and in predicting 
metastasis.
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